111 related articles for article (PubMed ID: 32422006)
1. Review: Oncogenic Insertional Mutagenesis as a Consequence of Retroviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Disease.
Ahmed B; Zafar M; Qadir MI
Crit Rev Eukaryot Gene Expr; 2019; 29(6):511-520. PubMed ID: 32422006
[TBL] [Abstract][Full Text] [Related]
2. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
3. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
[TBL] [Abstract][Full Text] [Related]
4. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
5. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy.
Pike-Overzet K; van der Burg M; Wagemaker G; van Dongen JJ; Staal FJ
Mol Ther; 2007 Nov; 15(11):1910-6. PubMed ID: 17726455
[TBL] [Abstract][Full Text] [Related]
6. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis.
Knight S; Collins M; Takeuchi Y
Curr Gene Ther; 2013 Jun; 13(3):211-27. PubMed ID: 23590635
[TBL] [Abstract][Full Text] [Related]
7. Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.
Newrzela S; Cornils K; Heinrich T; Schläger J; Yi JH; Lysenko O; Kimpel J; Fehse B; von Laer D
Mol Med; 2011; 17(11-12):1223-32. PubMed ID: 21826372
[TBL] [Abstract][Full Text] [Related]
8. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
[TBL] [Abstract][Full Text] [Related]
9. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
Ryu BY; Evans-Galea MV; Gray JT; Bodine DM; Persons DA; Nienhuis AW
Blood; 2008 Feb; 111(4):1866-75. PubMed ID: 17991809
[TBL] [Abstract][Full Text] [Related]
10. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.
Scobie L; Hector RD; Grant L; Bell M; Nielsen AA; Meikle S; Philbey A; Thrasher AJ; Cameron ER; Blyth K; Neil JC
Mol Ther; 2009 Jun; 17(6):1031-8. PubMed ID: 19337236
[TBL] [Abstract][Full Text] [Related]
11. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.
McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH
Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513
[TBL] [Abstract][Full Text] [Related]
12. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
Hacein-Bey-Abina S; Garrigue A; Wang GP; Soulier J; Lim A; Morillon E; Clappier E; Caccavelli L; Delabesse E; Beldjord K; Asnafi V; MacIntyre E; Dal Cortivo L; Radford I; Brousse N; Sigaux F; Moshous D; Hauer J; Borkhardt A; Belohradsky BH; Wintergerst U; Velez MC; Leiva L; Sorensen R; Wulffraat N; Blanche S; Bushman FD; Fischer A; Cavazzana-Calvo M
J Clin Invest; 2008 Sep; 118(9):3132-42. PubMed ID: 18688285
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for severe combined immunodeficiencies and beyond.
Fischer A; Hacein-Bey-Abina S
J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
[TBL] [Abstract][Full Text] [Related]
14. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of T-Cell-Specific Transcription Factor Expression in Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL).
Sayitoğlu M; Erbilgin Y; Hatırnaz Ng O; Yıldız I; Celkan T; Anak S; Devecioğlu O; Aydoğan G; Karaman S; Sarper N; Timur C; Ure U; Ozbek U
Turk J Haematol; 2012 Dec; 29(4):325-33. PubMed ID: 24385720
[TBL] [Abstract][Full Text] [Related]
17. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
Howe SJ; Mansour MR; Schwarzwaelder K; Bartholomae C; Hubank M; Kempski H; Brugman MH; Pike-Overzet K; Chatters SJ; de Ridder D; Gilmour KC; Adams S; Thornhill SI; Parsley KL; Staal FJ; Gale RE; Linch DC; Bayford J; Brown L; Quaye M; Kinnon C; Ancliff P; Webb DK; Schmidt M; von Kalle C; Gaspar HB; Thrasher AJ
J Clin Invest; 2008 Sep; 118(9):3143-50. PubMed ID: 18688286
[TBL] [Abstract][Full Text] [Related]
18. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Adams S; Howe SJ; Al Ghonaium A; Bayford J; Brown L; Davies EG; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra79. PubMed ID: 21865537
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.
Zhou S; Fatima S; Ma Z; Wang YD; Lu T; Janke LJ; Du Y; Sorrentino BP
Mol Ther; 2016 Jun; 24(6):1090-1099. PubMed ID: 26957223
[TBL] [Abstract][Full Text] [Related]
20. The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.
Shields BJ; Slape CI; Vo N; Jackson JT; Pliego-Zamora A; Ranasinghe H; Shi W; Curtis DJ; McCormack MP
Leukemia; 2019 Aug; 33(8):1868-1880. PubMed ID: 30700838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
